Published online May 14, 2014. doi: 10.3748/wjg.v20.i18.5171
Revised: January 12, 2014
Accepted: March 12, 2014
Published online: May 14, 2014
Processing time: 165 Days and 23.3 Hours
Compared to standard endoscopy, endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS) are often lengthier and more complex, thus requiring higher doses of sedatives for patient comfort and compliance. The aim of this review is to provide the reader with information regarding the use, safety profile, and merits of propofol for sedation in advanced endoscopic procedures like ERCP and EUS, based on the current literature.
Core tip: There is a plethora of data to support the safety profile of propofol in general endoscopy, and many studies that support non-anesthesiologist administered propofol. There are also compelling data that support its use in endoscopic retrograde cholangiopancreatography and endoscopic ultrasound. In the world of advanced therapeutic endoscopy, where patient burden, risk, and cost are high, propofol based sedation delivered by non-anesthetic, but appropriately trained individuals, should become the new standard.